Direct accesses

  • Go to main menu
  • Go to main content
Menu
GenSight GenSight
Search the site
  • Contact
  • Careers
  • You are viewing the website in English en
  • fr
Search the site
  • Whowe are
    • Company
    • Leadership
    • Collaborations
  • Diseaseswe target
    • Diseases we target
    • Leber Hereditary Optic Neuropathy (LHON)
    • Retinitis Pigmentosa (RP)
    • Geographic Atrophy in Dry-AMD
  • Ourtechnologies
    • Technologies we are applying
    • Gene Therapy
    • Mitochondrial Targeting Sequence (MTS)
    • Optogenetics
    • Clinical development Summary
  • Investors
    • Company Overview
    • Financial press releases
    • Investor Newsletters
    • Events & presentations
    • Stock information & Financial agenda
    • Governance
    • Documentation
  • Media

GS010 - LUMEVOQ

17 October 2024

GenSight Biologics Announces LUMEVOQ® Scientific Updates at AAO 2024

04 June 2024

GenSight Biologics to Present at Upcoming Medical Conferences and Stakeholder Meetings

20 March 2024

GenSight Biologics Confirms Sustained Efficacy and Safety of Bilateral LUMEVOQ® Injections Four Years After One-Time Administration

12 March 2024

GenSight Biologics Announces Initial Results from New Meta-Analyses on Visual Outcomes with LUMEVOQ® Gene Therapy at NANOS 2024

06 March 2024

GenSight Biologics Announces Update on Real-World Data from Early Access Programs of LUMEVOQ® Gene Therapy at NANOS 2024

04 March 2024

GenSight Biologics Announces LUMEVOQ® Scientific Updates at NANOS 2024

15 November 2023

GenSight Biologics Confirms 2nd Successful GMP Batch of LUMEVOQ® and Eligibility to Draw Down Bridge Financing 2nd Tranche of €4 million

13 November 2023

GenSight Biologics Announces Preliminary Assay Indicating Successful Manufacture of Second LUMEVOQ® GMP Batch

27 September 2023

GenSight Biologics Provides Update on European Medicines Agency Scientific Advice for LUMEVOQ®

18 September 2023

GenSight Biologics Announces Successful Manufacture of LUMEVOQ® GMP Batch

  • View previous 9 articles
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • …
  • 17
  • View next 9 articles
© 2025 Gensight Biologics
  • Terms of use
  • Sitemap
  • Contact
  • Credits
  • Cookies management
Go back to the page of the page